BioSig Completes 100th Patient Case with PURE EP(TM) System
February 19 2020 - 7:33AM
- Commercialization and install plan ahead of
schedule
- Installations at new centers are driving patient
enrollments and clinical data collection
BioSig Technologies, Inc. (NASDAQ: BSGM)
(“BioSig” or the “Company”), a medical technology company
developing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals, today announced that the Company
successfully completed 100 patient cases with its PURE EP(tm)
System.
The Company initiated its first clinical trial
in November 2019, and is currently enrolling patients at Texas
Cardiac Arrhythmia Institute at St. David’s Medical Center and Mayo
Clinic’s Florida campus. Earlier in 2019 the Company conducted
patient cases at Indiana University School of Medicine, Greenville
Memorial Hospital, Santa Barbara Cottage Hospital and Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center. The Company’s
PURE EP(tm) System was used during the procedures on patients with
persistent atrial fibrillation, ischemic ventricular tachycardias,
PVC, atypical flutters and other types of complex arrhythmias.
Clinical observations collected with PURE EP(tm)
System were recently presented by Andrea Natale, M.D., Executive
Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s
Medical Center during the 25th Annual International AF Symposium.
Management is encouraged by the level of interest in commercial
deployments from over 40 leading U.S. based medical centers
generated at this event.
“We are responding to the requests in a
methodical fashion in order to assess and meet the needs of these
centers. We are running ahead of our plans stated in our November
2019 shareholder letter, based on the number of centers we are
currently engaging to discuss potential new installations,”
commented Kenneth L. Londoner, Chairman and CEO of BioSig
Technologies, Inc. The Company’s most recent Shareholder Letter
stated the intentions to install PURE EP(tm) System at up to nine
new centers leading up to the Heart Rhythm Society’s annual
convention in May 2020.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a
proprietary biomedical signal processing platform designed to
improve the electrophysiology (EP) marketplace
(www.biosig.com).
The Company’s first product, PURE EP(tm) System
is a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
Forward-looking Statements This
press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
- PURE EP(TM) System
- BioSig Technologies Inc. Team
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024